Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Inverness acquires Matritech to offer bladder cancer urine test

Inverness Medical Innovations : 21 April, 2008  (New Product)
Inverness Medical has acquired Matritech to offer the NMP22 BladderChek Test and NMP22 Test Kit for the rapid diagnosis and monitoring of early stage bladder cancer.
More commonly seen in men than women at a ratio of 3:1 (Ref 1), bladder cancer is linked to smoking and exposure to industrial chemicals, with approximately 356,600 new cases of bladder cancer reported worldwide each year1.

Simple to use, the rapid BladderChek Test can be performed outside of the laboratory with reliable results available during a single patient visit in just 30 minutes. Requiring only four drops of urine, the test is unaffected by the presence of blood in the sample which is commonly seen as one of the first symptoms of bladder cancer.

The painless and non-invasive Assay makes the NMP22 BladderChek Test and NMP22 Test Kit ideal for initial assessment as well as for monitoring before a cystoscopy is performed.

Both the rapid format and the ELISA test from Inverness Medical detect for elevated amounts of Nuclear Matrix protein (NMP22) in urine samples. Elevated amounts of NMP22 are present in the urine of most individuals with bladder cancer and are detectable even at early stages of the disease, making it an ideal marker for early diagnosis.

Bladder cancer has the highest rate of recurrence at 50 to 90 percent depending on the initial aggressiveness of the tumour. The NMP22 BladderChek Test and NMP22 Test Kit provide clinicians with the tools for an effective at risk-group screening and monitoring program in addition to cystoscopy procedures. This allows for rapid, accurate and cost effective detection of bladder cancer.

Ref 1 - IARC. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide (2002 estimates).
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo